Cost effectiveness

Value in the Cath Lab: Contemporary Use of GP IIb/IIIa Inhibitors in the Treatment of ACS at the Mayo Clinic Heath System

07/09/2016

Eric H. Yang , MD;

In terms of choosing which GP IIb/IIIa inhibitor to use, what historically has just been a two-person game, is now a three-person game that includes abciximab, eptifibatide, and tirofiban.

In terms of choosing which GP...

07/09/2016

Cath Lab Digest

Daratumumab More Cost Effective for Multiple Myeloma Treatment

06/13/2016

JCP Editors

Daratumumab may be the most cost-effective treatment option for patients with multiple myeloma (MM) compared with other novel therapies, according to a poster presented at the 2016 American Society of Clinical...

...

06/13/2016

Journal of Clinical Pathways

Research Reports

Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations

05/06/2016

Rakesh Luthra , MS;

Jonathan Graham , BS;

Stephanie Earnshaw , PhD;

Rohit Borker , PhD;

Jonathan Lim , BS, MS, MSc;

Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...

...

05/06/2016

Journal of Clinical Pathways

Applying a Cost-Effectiveness Methodology to Angina

01/13/2015

David J. Cohen , MD, MPH, MSc;

There are many causes of angina, but what is very clear from research that has been done over the last several decades is that angina has an important impact on patients’ quality of life. It limits the activities they do, it limits their...

There are many causes of angina,...

01/13/2015

Cath Lab Digest

Clinical and Economic Advantages of the iFR Modality for Physiologic Assessment

12/05/2014

Bruce A. Samuels , MD;

Approved by the FDA in March 2014, iFR is a diagnostic tool used to assess whether a stenosis is causing a limitation of blood flow in coronary arteries with subsequent ischemia. This tool preserves the advantages of physiology-based...

Approved by the FDA in March...

12/05/2014

Cath Lab Digest

Original Research

Trends in the Incidence of Carotid Body Tumors in the United States From 1998 to 2011

12/03/2014

Anahita Dua , MD, MS, MBA, FACS;

Sapan S. Desai , MD, PhD, MBA;

Tanner C. Spees , MD;

Francisco C. Hernandez , MD;

Anthony A. Igbadumhe , MD;

Mohammed Algodi , MD;

The authors conducted a retrospective analysis of hospital discharge data to determine national trends in carotid body tumors in the United States by year, incidence, patient demographics, and hospital covariates.

The authors conducted a...

12/03/2014

Vascular Disease Management